跳至主要内容
临床试验/EUCTR2012-001208-39-AT
EUCTR2012-001208-39-AT进行中(未招募)不适用

A new therapeutic approach to prevent acute insulin-mediated complications in type 2 diabetes Subtitle: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin LEvemir® vs. cOnventional insulin therapy: GALILEO - GALILEO

Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel0 个研究点开始时间: 2012年4月17日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Type 2 diabetes
  • Currently under oral glucose lowering medication
  • Insufficient metabolic control: HbA1C > 8%
  • Patient understands study procedure and gives written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 32
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Age < 18 years
  • Type 1 Diabetes, LADA-Diabetes
  • Prior insulin administration/therapy
  • Therapy with thiazolidiones
  • Known cardiovascular disease (history of myocardial infarction, stroke etc)
  • Severe arterial hypertension
  • Acute or chronic inflammatory disease within 2 weeks prior the study
  • Kidney or liver disease
  • Psychiatric disorder
  • Tendency towards claustrophobia
  • metal devices or other magnetic material in or on the subjects body which will be hazardous for NMR investigation

研究者

发起方
Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel

相似试验